Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Polycystic Ovary Syndrome 2Neoplasms 2Diabetes Mellitus, Type 2 2Thyroid Cancer, Papillary 1Solid Cancers 1Sezary Syndrome 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Obesity 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Liposarcoma 1Leukoplakia, Oral 1Carcinoma, Renal Cell 1Breast Neoplasms 1Alzheimer Disease 1Adenocarcinoma, Follicular 1

Interventions

Doxorubicin 80Ifosfamide 54Radiotherapy 43Filgrastim 41Gemcitabine 38Cyclophosphamide 34Etoposide 26Vincristine 24Cisplatin 24Docetaxel 23pazopanib 21Trabectedin 19Carboplatin 17pembrolizumab 15Peripheral Blood Stem Cell Transplantation 14eribulin 12Mesna 12Melphalan 12Sorafenib 11Sirolimus 11Irinotecan 11Granulocyte Colony-Stimulating Factor 11Bevacizumab 11Topotecan 10Paclitaxel 10Imatinib Mesylate 10Chemotherapy, Adjuvant 10pegfilgrastim 9Temozolomide 9Surgical Procedures, Operative 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sarcoma × Rosiglitazone × Clear all
NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed
32 enrolled
Sarcoma

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡